Roivant’s Lung Drug Posted a Record Trial Result. Is 19% Enough?

There is one FDA-approved inhaled therapy for pulmonary hypertension associated with interstitial lung disease. One. United Therapeutics has owned that ground with Tyvaso since 2021, and the franchise generated $452.6 million in revenue in the second quarter of 2026 alone. Tuesday morning, Roivant Sciences gave the market its first credible reason to ask whether that monopoly has an expiration date.

What the PHocus Data Actually Said

PH-ILD is a progressive and life-threatening condition with significant unmet medical needs for patients. As Roivant’s President Mayukh Sukhatme put it, “PH-ILD is a disease as bad as some forms of cancer, with a median survival of just 1.5-2 years despite best-available standard of care.”

Pulmovant reported topline data from its Phase 2 PHocus trial evaluating mosliciguat in 135 patients with PH-ILD. The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful 56.3% placebo-adjusted reduction in pulmonary vascular resistance, a key measure of disease severity. That figure is not just good; it is the highest ever reported PVR reduction in any randomized controlled PH trial, based on the company’s stated comparison.

Patients receiving mosliciguat walked 35.2 meters farther than those on placebo in a six-minute walk test, and the drug produced a significant reduction in NT-proBNP, a biomarker of cardiac strain. Secondary endpoints cleared. The Phase 3 PHrontier study is already enrolling.

The Mechanism Is the Differentiation

The clinical numbers matter, but the biology behind them matters more for gauging long-term competitive position. Tyvaso works through prostacyclin pathways. Mosliciguat does not go near them.

Mosliciguat directly activates the heme-free, nitric-oxide-unresponsive form of soluble guanylate cyclase, the form that accumulates in damaged, oxidized tissue. While sGC stimulators can be used to treat pulmonary hypertension, they require heme and nitric oxide. In PH-ILD, oxidative stress can shift sGC toward heme-free forms and impair nitric oxide signaling. Mosliciguat is designed to work without them, potentially retaining efficacy in the highly oxidative environment where stimulators may lose it.

The dosing contrast with Tyvaso is also real. Unlike the multiple daily inhalation sessions required by Tyvaso, mosliciguat is being developed as a once-daily inhaled therapy. That is not a minor commercial footnote. Patient compliance in a disease this severe is a genuine determinant of outcomes, and once-daily inhalation is a meaningful step down in burden.

Sizing the Opportunity

Up to 200,000 patients across the U.S. and Europe are living with PH-ILD, with limited or no approved treatment options. In Europe, approvals and access vary by country, and the treatment landscape is more limited than in the U.S. That means the addressable population is still meaningfully under-served across major markets mosliciguat could eventually reach.

Based on Tyvaso’s pricing, PH-ILD represents a large market opportunity in the U.S. alone. Even a modest share of that, bolted onto a Phase 3 that replicates Tuesday’s results, would be transformative for a company that reported about $3.8 billion in cash, cash equivalents, and marketable securities as of June 30, 2026 and recently secured its first commercial approval with Lisraya for dermatomyositis.

Is the 19% Move the Start or the Whole Story?

Roivant soared to a new all-time high Tuesday, touching $42.50 intraday before closing up roughly 19% at $41.48. The premarket move was reported near 24% before the broader session moderated gains. Either way, the move was largely company-specific, with broader biotech indices trading mixed on the day, which means the market was pricing mosliciguat, not riding a sector wave.

Phase 2 wins of this magnitude routinely price in a probability of Phase 3 success, not certainty of it. The PHrontier trial will run against a harder endpoint environment with more patients and more regulatory scrutiny. United Therapeutics is not sitting still either: the company has said it anticipates the FDA review for nebulized Tyvaso in idiopathic pulmonary fibrosis to be complete in late April 2027, and it continues to develop next-generation treprostinil delivery approaches. The incumbent is not surrendering the indication.

Risks Worth Watching

• Phase 3 replication risk. A 56% PVR reduction is remarkable. Maintaining that effect size in a larger, more diverse Phase 3 population is a separate and harder task.
• Competitive timing. United Therapeutics anticipates an FDA decision for nebulized Tyvaso in idiopathic pulmonary fibrosis in 2027, and it continues to advance other treprostinil delivery programs. The window before Roivant could reach the market is not empty.
• Combination vs. replacement. Mosliciguat may ultimately land as an add-on to Tyvaso rather than a standalone substitute, which changes revenue ceiling projections considerably.

The Bigger Picture

Roivant’s model is to license shelved molecules from large pharma, house them in focused subsidiaries, and push them through development faster than their original owners would have. Mosliciguat was in-licensed from Bayer. It now carries the biggest PVR reduction reported in a randomized controlled PH trial, based on the company’s stated comparison. That is either a coincidence or a validation of the model.

With Phase 3 enrollment underway and a condition affecting up to 200,000 patients in two continents still lacking a second FDA-approved option, the stock’s move Tuesday may look modest in hindsight if PHrontier delivers. Or it may prove to be the high-water mark of a Phase 2 moment that Phase 3 reality tempers. ROIV is worth watching closely. The next inflection is already in motion.